Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The present study aimed to investigate the effects of a 4-week repeated oral intake of a quercetin-containing supplement on allergen-induced reactions and relative subjective symptoms in Japanese adults who complained of discomfort in the eyes and nose.

Who Took Part

According to the abstract, 66 subjects were involved.

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults.

A randomized, placebo-controlled, double-blind parallel-group study was conducted on 66 subjects (22-78 years old) with allergic symptoms of pollinosis.

The Japanese Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ) scores and other tests were examined in each subject before and after starting the product intake.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Groups ran in parallel: each of the subjects stayed in one arm throughout.

A new food-grade bioavailable formulation of quercetin, Quercetin phytosome®, was used.

What Was Measured

Topics PubMed links to this paper include Allergens, Quality of Life, Quercetin and Rhinitis, Allergic, Seasonal.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 66 subjects.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (European review for medical and pharmacological sciences), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.